{"id":3982,"date":"2023-07-05T11:59:04","date_gmt":"2023-07-05T11:59:04","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/poster\/pulmocide\/"},"modified":"2026-01-22T17:24:59","modified_gmt":"2026-01-22T17:24:59","slug":"pulmocide","status":"publish","type":"poster","link":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/","title":{"rendered":"Discovery of Opelconazole (PC945): A Novel Antifungal Agent for inhaled Administration"},"content":{"rendered":"

Within our poster, we report the development of Opelconazole (PC945) a novel, inhaled triazole antifungal agent for the treatment of respiratory fungal infections. PC945 is a potent inhibitor of CYP51, purpose-designed to be administered via<\/em> inhalation for high local lung concentrations and limited systemic exposure.<\/span><\/h2>\n

The US Food and Drug Administration (FDA) has granted Orphan Drug, Fast Track and Qualified Infectious Disease Product designations for Opelconazole (PC945) for the treatment of IPA. PC945 has been used on a \u201cspecial needs\u201d basis in the UK in patients who have not responded to multiple standard-of-care (SOC) antifungal therapies, with remarkable results.\u00a0 A Phase 3 study of PC945 for the treatment of IPA as part of a combined antifungal regimen was initiated in 2022.<\/p>\n

Pulmocide<\/a> is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections. For this collaboration, Sygnature Discovery supplied all medicinal chemistry services, with a team led by Dr Mihiro Sunose<\/a>, and are named inventors for PC945.<\/p>\n

Presented at ACS Fall<\/a>, San Francisco, Aug 13-17th<\/sup> 2023 by Dr Andrew Novak<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Explore our poster detailing the development of Opelconazole (PC945), an innovative inhaled antifungal for respiratory infections. With Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations from the FDA, PC945 has shown remarkable potential, benefiting from a Phase 3 study initiated in 2022. This collaboration with Pulmocide showcases Sygnature Discovery’s medicinal chemistry expertise, led by Dr. Mihiro Sunose.<\/p>\n","protected":false},"featured_media":2640,"template":"","category":[682,678,713],"class_list":["post-3982","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-chemistry","category-integrated-drug-discovery","category-medicinal-chemistry"],"acf":[],"yoast_head":"\nOpelconazole (PC945): Novel Inhaled Antifungal Discovery<\/title>\n<meta name=\"description\" content=\"Discover the development of Opelconazole (PC945), an inhaled antifungal with FDA designations, in our collaborative Pulmocide poster.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opelconazole (PC945): Novel Inhaled Antifungal Discovery\" \/>\n<meta property=\"og:description\" content=\"Discover the development of Opelconazole (PC945), an inhaled antifungal with FDA designations, in our collaborative Pulmocide poster.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T17:24:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/pulmocide-poster.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"728\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/pulmocide\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/pulmocide\\\/\",\"name\":\"Opelconazole (PC945): Novel Inhaled Antifungal Discovery\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/pulmocide\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/pulmocide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/pulmocide-poster.png\",\"datePublished\":\"2023-07-05T11:59:04+00:00\",\"dateModified\":\"2026-01-22T17:24:59+00:00\",\"description\":\"Discover the development of Opelconazole (PC945), an inhaled antifungal with FDA designations, in our collaborative Pulmocide poster.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/pulmocide\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/pulmocide\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/pulmocide\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/pulmocide-poster.png\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/pulmocide-poster.png\",\"width\":14361,\"height\":10210},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/pulmocide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Discovery of Opelconazole (PC945): A Novel Antifungal Agent for inhaled Administration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opelconazole (PC945): Novel Inhaled Antifungal Discovery","description":"Discover the development of Opelconazole (PC945), an inhaled antifungal with FDA designations, in our collaborative Pulmocide poster.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/","og_locale":"fr_CA","og_type":"article","og_title":"Opelconazole (PC945): Novel Inhaled Antifungal Discovery","og_description":"Discover the development of Opelconazole (PC945), an inhaled antifungal with FDA designations, in our collaborative Pulmocide poster.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/","og_site_name":"Sygnature","article_modified_time":"2026-01-22T17:24:59+00:00","og_image":[{"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/pulmocide-poster.png","width":1024,"height":728,"type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/","name":"Opelconazole (PC945): Novel Inhaled Antifungal Discovery","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/pulmocide-poster.png","datePublished":"2023-07-05T11:59:04+00:00","dateModified":"2026-01-22T17:24:59+00:00","description":"Discover the development of Opelconazole (PC945), an inhaled antifungal with FDA designations, in our collaborative Pulmocide poster.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/pulmocide-poster.png","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/pulmocide-poster.png","width":14361,"height":10210},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/pulmocide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Discovery of Opelconazole (PC945): A Novel Antifungal Agent for inhaled Administration"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/poster"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3982\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/2640"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=3982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=3982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}